Molecular switch system with signal cascade amplification and application thereof
By designing a molecular switch system and combining the araC gene, pTet promoter, tetR gene, and tetO operon, a forward and reverse regulatory system was constructed, which solved the problems of leakage expression and slow response speed of the CRISPRi system and achieved a more efficient gene regulation effect.
Patent Information
- Application Number
- CN202510614871.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-13
- Publication Date
- 2025-08-01
AI Technical Summary
The existing CRISPRi system suffers from leakage expression in bacteria, slow response speed, limited regulatory range, low metabolic allocation efficiency, and difficulty in achieving independent and bidirectional regulation of multiple target genes.
A molecular switch system was designed, comprising the sequentially linked activator araC gene, bidirectional pTet promoter, repressor tetR gene, pBad promoter, and tetO operon, constructing forward and reverse regulatory systems, and achieving precise regulation using the dCas12a gene and constitutive promoter.
It achieves lower background leakage, faster response rate, larger expression range and stronger expression intensity, more homogeneous expression, and significantly improved inhibition efficiency.
Smart Images

Figure BDA0005401728420000081 
Figure HDA0005401728450000011 
Figure HDA0005401728450000012
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and particularly to a molecular switch system with signal cascade amplification and its applications. Background Art
[0002] With the development of synthetic biology, people have paid increasing attention to expanding the complexity of engineered genetic circuits. In particular, the research on hybrid promoters and logic gating systems will become an important reference for the future design and development of synthetic biological systems. Traditional inducible promoters include derepressed promoters (such as pTet) and activating promoters (such as pBad), which are often limited by the strength of their inherent promoters, have relatively high levels of leaky expression, and require a long response time.
[0003] Traditional biosensor devices directly achieve the regulation of gene expression or inhibition through a single promoter and CRISPRi. There has been a study using the pTet promoter to control CRISPRi based on dCas9 to achieve targeted inhibition of a target gene. An expression strain using a dCas9 protein driven by an aTc-inducible pTet promoter and an sgRNA expression cassette driven by a constitutive promoter showed lower fluorescence intensity than the control strain in the presence of 100 ng / mL aTc.
[0004] Although the CRISPRi system has many advantages, there are still some limitations that deserve further improvement. First, in the absence of an inducer, the leaky expression of CRISPRi may lead to background gene silencing. In addition, high-level CRISPRi expression may have a negative impact on cell growth and morphology. Previous studies have shown that Escherichia coli exhibits abnormal filamentous morphology and its growth is severely inhibited under high-level Cas protein expression. Therefore, precise regulation of intracellular Cas protein levels needs to be considered when using the CRISPRi system in microorganisms.
[0005] In summary, the existing bacterial expression regulation systems have insufficient precision, lagging response speed, limited regulation amplitude, and low metabolic allocation efficiency. The CRISPR controlled by the traditional expression system has leaky expression in the unactivated state, resulting in biomass loss and unable to achieve precise temporal regulation. Moreover, the regulation means are single, and it is difficult to achieve independent and bidirectional regulation of multiple target genes. Summary of the Invention
[0006] In view of this, the technical problem to be solved by the present invention is to provide a molecular switch system with signal cascade amplification and its applications.
[0007] The present invention provides a molecular switch, which comprises an activating protein araC gene, a bidirectional pTet promoter, a repressor protein tetR gene, a pBad promoter, and a tetO operator, which are connected in sequence.
[0008] In the present invention, the direction of the specific activating protein araC gene is opposite to the directions of the repressor protein tetR gene, the pBad promoter, and the tetO operator;
[0009] The present invention provides a positive regulation system, which includes the molecular switch described in the present invention and a target gene.
[0010] The present invention provides a reverse regulation system, which includes the molecular switch described in the present invention, the dCas12a gene, a constitutive promoter, and a crRNA targeting the target gene.
[0011] Furthermore, for the reverse regulation system described in the present invention,
[0012] the coding product of the dCas12a gene is derived from Francisella novicida U112 and has an E1006A mutation; specifically, the UniProtKB accession number of Cas12a derived from Francisella novicida U112 is: A0Q7Q2. The present invention has performed an E1006A mutation and codon optimization on it.
[0013] The constitutive promoter includes the pLac promoter.
[0014] The present invention provides a recombinant vector, which includes a vector backbone and at least one of the following I) - III):
[0015] I), the molecular switch described in the present invention;
[0016] II), the positive regulation system described in the present invention;
[0017] III), the reverse regulation system described in the present invention.
[0018] The source of the vector backbone described in the present invention includes plants, animals, bacteria, fungi, bacteriophages, or viruses, and the present invention does not limit this.
[0019] The recombinant vector of the present invention refers to a recombinant nucleic acid vector, which is a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences or elements essential for the expression of the operably linked coding gene or for performing necessary genetic manipulations in a specific host organism. Once transformed into a suitable host, the vector can replicate and function independently of the host genome, or, in some cases, integrate into the genome itself. In this specification, "plasmid" and "vector" can sometimes be used interchangeably because plasmids are the most commonly used form of vectors currently. However, the present invention is intended to include such other forms of expression vectors that perform equivalent functions and are known or will become known in the art, including but not limited to: plasmids, bacteriophage particles, viral vectors, and / or merely potential genomic inserts. In specific embodiments, the nucleic acid encoding the fusion protein provided by the present invention can be constructed in various prokaryotic vectors. For example, its backbone vector can be a pBAD series vector, specifically pBad-sfGFP.
[0020] The present invention provides a host cell transfected or transformed with the recombinant vector as described in the present invention.
[0021] The present invention provides a host transfected or transformed with the recombinant vector. A host cell is transformed or transfected with a vector constructed using recombinant DNA technology, and such a transformed host cell has the ability to replicate the vector encoding the protein or express the desired protein or perform specific functions, such as gene silencing.
[0022] Furthermore, the transformation methods include: chemical transformation and electroporation; the transfection methods include calcium phosphate co-precipitation, liposome method, and viral transfection. The viral transfection includes adenovirus transfection, adeno-associated virus transfection, lentivirus transfection, etc.
[0023] The host cells provided by the present invention can be derived from plants, animals, bacteria, fungi, bacteriophages, or viruses, and the present invention does not limit this.
[0024] Further, the host includes at least one of E.coli Turbo, E.coli WM3064, S.oneidensis MR-1, or S.oneidensis GZ.
[0025] The present invention provides a method for constructing the recombinant vector, which includes culturing the host cell as described in the present invention to obtain the recombinant vector as described in the present invention.
[0026] The present invention provides a product for gene expression or regulation, which includes reagents for gene expression or regulation and at least one of the following i) - iii):
[0027] i), the recombinant vector as described in the present invention;
[0028] ii), the host cell of the present invention;
[0029] iii), the recombinant vector obtained by the construction method of the present invention;
[0030] Furthermore, in the product of the present invention, the reagent for gene expression or regulation includes buffer, antibiotic, culture medium and / or conjugation transfer ligand bacteria.
[0031] The present invention provides the application of any one of the following A) - G) in gene expression and / or regulation:
[0032] A), the molecular switch of the present invention;
[0033] B), the positive regulation system of the present invention;
[0034] C), the negative regulation system of the present invention;
[0035] D), the recombinant vector of the present invention;
[0036] E), the host cell shown in the present invention;
[0037] F), the recombinant vector obtained by the construction method of the present invention;
[0038] G), the product of the present invention.
[0039] The regulation includes increasing and / or decreasing. In the present invention, CRISPRi is used to achieve knockdown of the target gene.
[0040] The present invention provides a molecular switch having an input module for sensing an input signal, a processing module for signal processing, and an execution module for output execution. The molecular switch specifically includes an activator protein araC gene, a bidirectional pTet promoter, a repressor protein tetR gene, a pBad promoter, and a tetO operator connected in sequence from upstream to downstream; the gene switch can be directly connected to the target gene to construct a positive regulation system for the expression of the target gene; the experimental results show that compared with the single pTet in the comparative document and the prior art pBad expression system, the novel positive regulation system pAND of the present invention has lower background leakage, faster response rate, larger expression range, stronger expression intensity, and more homogeneous expression. Moreover, the molecular switch of the present invention can also be combined with a gene silencing system to construct a negative regulation system. The experimental results show that compared with the 64% inhibition efficiency achieved by assembling CRISPRi (pBad-CRISPRi) under a common induction system, the negative regulation recombinant plasmid pAND-CRISPRi of the present invention can achieve a 90% inhibition efficiency.
[0041] In addition, the present invention also screened and reorganized some elements of the molecular switch and negative regulatory system, including mutation of element nucleotides, codon optimization, and position exchange. Specifically, the dCas12a gene was codon optimized and mutated; the test results showed that after the above optimization, the molecular switch with better performance described in the present invention was obtained.
[0042] The present invention provides a molecular switch for a signal cascade method and a system for gene expression and / or regulation. The molecular switch comprises an activator protein araC gene, a bidirectional pTet promoter, a repressor protein tetR gene, a pBad promoter, and a tetO operator, connected from upstream to downstream. When used to express or silence a target gene, the molecular switch exhibits lower background leakage, faster response rates, a wider expression range, stronger expression intensity, more homogeneous expression, and significantly improved inhibition efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 Shown is the plasmid map of pBad-sfGFP:
[0044] Figure 2 shows the plasmid map of pTet-sfGFP;
[0045] Figure 3 shows the pBad-CRISPRi plasmid map;
[0046] Figure 4 Shown is the pBad-CRISPRi plasmid map.
[0047] Figure 5 Figure 2 shows a schematic diagram of a precise regulation system—a molecular switch. The molecular switch consists of three functional modules: an input module, a processing module, and an execution module. The input module is controlled by both a trigger signal and a regulatory signal. The regulatory signal relieves the repressor protein from inhibiting the operon, thereby initiating the expression and accumulation of the activator protein. In the processing module, only when the regulatory signal relieves the operon can the trigger signal bind to the activator protein, further driving the expression of the execution module. The execution module can be used to directly express target gene 1 or to express a dCas12a-based inverter to selectively inhibit target gene 2 with the help of specific crRNA.
[0048] Figure 6 The figure shows the plasmid map of the positive regulation recombinant plasmid, which includes the plasmid backbone, repressor protein tetR gene, pTet promoter, activator protein araC gene, pBad promoter, tetO operator and target gene 1;
[0049] Figure 7Plasmid map of the recombinant plasmid for negative regulation; it includes a plasmid backbone, the repressor protein tetR gene, the pTet promoter, the activator protein araC gene, the pBad promoter, the tetO operator, the dSoFnCas12a gene, the constitutive pLac promoter, and the crRNA targeting the target gene 2;
[0050] Figure 8 Expression result diagram of the positive regulation system. When the target gene 1 takes sfGFP as an example, the green fluorescence intensity at different inducer concentrations. Among them, pBad-sfGFP is a plasmid expressing sfGFP under the traditional P Bad promoter; pAND-sfGFP is a plasmid expressing sfGFP of the positive regulation system responding to L-Ara and aTc signals;
[0051] Figure 9 Shows the maximum output fluorescence after activation at different time points; the maximum fluorescence values after induction at different time points without induction or with 20 mM L-Ara and 20 μg / L aTc;
[0052] Figure 10 Shows the fluorescence response rate after activation at different time points; the fluorescence growth slopes after induction at different time points without induction or with 20 mM L-Ara and 20 μg / L aTc;
[0053] Figure 11 Shows the proportion of high-fluorescence strains. The proportion of high-fluorescence cells in the total cells after activation by 20 mM L-Ara and 20 μg / L aTc at 3 h and 6 h of inoculation;
[0054] Figure 12 Shows the inhibition result diagram of the negative regulation system; when the target gene 2 takes GFPmut3b as an example, the green fluorescence intensity of the S.oneidensis GZ strain after targeted inhibition by the traditional pBad-CRISPRi and the negative regulation system pAND-CRISPRi at different inducer concentrations. Detailed implementation method
[0055] The present invention provides a molecular switch system with signal cascade amplification and its applications. Those skilled in the art can draw on the content of this article and appropriately modify the process parameters to achieve. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and those related can obviously make changes or appropriate alterations and combinations to the methods and applications in this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0056] The plasmid vector and the promoter are derived from the starting plasmid pBad-sfGFP(Figure 1 )、pTet-sfGFP( Figure 2 )、pBad-CRISPRi( Figure 3 )、pLac-mCherry( Figure 4 );
[0057] The molecular switch of the present invention consists of three modules: an input module for sensing input signals, a processing module for signal processing, and an execution module for output execution, specifically as Figure 5 .
[0058] The map of pAND constructed in the present invention is as Figure 6 ;
[0059] The map of pAND-CRISPRi constructed in the present invention is as Figure 7 .
[0060] The said pAND promoter includes an araC activator gene controlled by a pTet promoter and a pBad promoter;
[0061] Preferably, the dSoFnCas12a gene is a codon-optimized dCas12a gene derived from Francisella novicida U112 with an E1006A mutation;
[0062] The present invention provides a plasmid system for a novel expression regulation system, which is used to achieve precise positive regulation, negative regulation, and bidirectional regulation.
[0063] The relevant gene sequences used in the present invention are obtained from the public database of Pubmed (http: / / www.pubmed.com / ).
[0064] Table 1. Primers
[0065] Primer Sequence (5’-3’) Sequence ID pYY-1F ctcgaccactcgaggccaggcatc SEQ ID NO:1 pYY-1R ttggcaactctgcgtctgagaggtaccac SEQ ID NO:2 araC-1F cctctcagacgcagagttgccaacatcgatttattatgacaacttgacggc SEQ ID NO:3 araC-1R caaaagatctaaagaggagaaaggatctatggctgaagcgcaaaatgatcccctg SEQ ID NO:4 pBad-1F ctgcttactgaatttcggtggtgcagagaagaaaccaattgtccatattgc SEQ ID NO:5 tetO-pBad-1R ctctttaatgaattcctctatcactgatagggagcaaaaaaacgggtatggagaaacag SEQ ID NO:6 pTet-1F agatcctttctcctctttagatcttttgaattcttttctctatcactgatag SEQ ID NO:7 pTet-1R caccaccgaaattcagtaagcagaaag SEQ ID NO:8 sfGFP-1F tcagtgatagaggaattcattaaagaggagaaaggtaccatgagcaaaggagaagaact SEQ ID NO:9 sfGFP-1R gatgcctggcctcgagtggtcgagttacgctgcaagggcgtaattttcg SEQ ID NO:10 dCas12a-2F gatagaggaattcattaaagaggagaaaggtaccatgtctatctaccaagaattcgtta SEQ ID NO:11 dCas12a-2R catttcgaaccccagagtcccgcttagttgttacggttttgaacgaat SEQ ID NO:12 pLac-2F gcgggactctggggttcgaaatg SEQ ID NO:13 pLac-2R atctacaacagtagaaattttccacacaacatacgagccggaagc SEQ ID NO:14 crRNA-2F aatttctactgttgtagatggacaactccagtgaaaagttctgtctgacgcgatagcat SEQ ID NO:15 CRRNA-2R gatgcctggcctcgagtggtcgaggcgttcttatgctatcgcgtcagacagaacttttc SEQ ID NO:16
[0066]
[0067]
[0068] Glossary of Terms:
[0069] aTc: Anhydrotetracycline
[0070] L-Ara: L-Arabinose
[0071] pBad promoter: An activating promoter. The activating protein AraC binds to the inducer L-Ara to initiate gene expression.
[0072] pTet promoter: A derepressible promoter that contains the repressor protein TetR and the operator tetO. TetR binds to tetO located between the promoter and the target gene, inhibiting gene expression. The inducer aTc can bind to TetR, causing it to dissociate from tetO, thereby initiating gene expression.
[0073] pLac promoter: A derepressible promoter that contains the repressor protein LacI and the operator lacO. LacI binds to lacO located between the promoter and the target gene, inhibiting gene expression. The inducer IPTG can bind to LacI, causing it to dissociate from lacO, thereby initiating gene expression. When LacI or lacO is absent, it is a constitutive expression promoter.
[0074] CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats
[0075] CRISPRi: CRISPR Interference
[0076] dCas12a: Dead Cas12a, a Cas12a protein with inactivated cleavage activity
[0077] sgRNA: Single Guide RNA
[0078] crRNA: CRISPR RNA, a type of sgRNA that guides the Cas protein to recognize and bind to the target DNA sequence
[0079] sfGFP: Superfolder Green Fluorescent Protein, a type of green fluorescent protein
[0080] GFPmut3b: Green Fluorescent Protein mut3b, a green fluorescent protein.
[0081] Table 2. Strains and plasmids used in the present invention
[0082]
[0083] The test materials used in the present invention are all common commercial products and can be purchased on the market. The present invention is further described below with reference to the following examples:
[0084] Example 1 Construction of a molecular switch cascade response system
[0085] In order to achieve rapid switching and precise control of gene expression, an expression regulation switch (such as the attached Figure 1 As shown). The switch consists of three modules: an input module that senses input signals, a processing module that processes the signals, and an execution module that executes the outputs. The expression level of the activating protein (such as AraC) in the cell is regulated by an adjustable signal (such as aTc), thereby triggering the response speed of the switch; and the trigger signal (such as L-Ara) acts as a trigger to activate the switch. In addition, the operator (such as tetO) of the repressor protein (such as TetR) corresponding to the adjustable signal (such as aTc) is positioned downstream of the output promoter to inhibit the basal expression caused by leakage in the inactivated state of the switch, thereby improving the dynamic range of the switch. The final designed execution module includes a positive output and a negative output formed by the introduction of the CRISPR-dCas12a system to form an inverting structure. This dual blocking and cascade amplification strategy aims to achieve robust regulation with high dynamics and high output intensity. Based on this, two recombinant plasmids, pAND and pAND-CRISPRi, were constructed; pAND is a positive regulation recombinant plasmid, which includes a plasmid backbone, a repressor protein tetR gene, a pTet promoter, an activator protein araC gene, a pBad promoter, a tetO operator, and a target gene 1 (GFP); pAND-CRISPRi is a negative regulation recombinant plasmid, which includes a plasmid backbone, a repressor protein tetR gene, a pTet promoter, an activator protein araC gene, a pBad promoter, a tetO operator, a dSoFnCas12a gene, a constitutive pLac promoter, and a crRNA targeting a target gene 2. The specific construction process is as follows:
[0086] 1. Strains, Plasmids, and Culture Methods
[0087] All strains and plasmids used in this invention are listed in Table 2. Among them, Escherichia coli Turbo is used for plasmid cloning and phenotypic verification of gene circuits, and E. coli WM3604 is used for conjugation experiments. All E. coli and Shewanella oneidensis strains are cultured in LB medium. For the medium of E. coli WM3604, 2,6-diaminopimelic acid (DAP) with a final concentration of 50 μM needs to be additionally added.
[0088] E. coli and S. oneidensis are cultured at 37 °C and 30 °C respectively. The formula of LB medium is as follows: 10 g / L tryptone, 5 g / L yeast extract, and 10 g / L NaCl; 15 g / L agar powder is added to the solid medium.
[0089] According to the experimental requirements, antibiotics and inducers are added to the medium. The antibiotic used is kanamycin, with a concentration of 50 mg / L. The inducers include anhydrotetracycline (aTc) and L-arabinose (L-Ara), and the corresponding concentrations are added according to specific experimental conditions.
[0090] The strains can be cultured under static conditions or placed in a shaker and cultured with shaking at 200 rpm. The growth of bacteria is monitored by measuring the optical density (OD 600 ) at 600 nm using an ultraviolet spectrophotometer (BioSpec-1601, Shimadzu Corporation, Japan).
[0091] II. Sequence analysis
[0092] The complete sequence data of the genomes of Escherichia coli MG1655 and Shewanella oneidensis MR-1 are obtained from the National Center for Biotechnology Information, NCBI (the taxonomic IDs are: txid511145 and txid211586 respectively).
[0093] III. Amplification of plasmid backbone and gene fragments
[0094] Genomic DNA was extracted using the E.Z.N.A. Genomic DNA Kit (Omega Bio-tek, Beijing, China). Plasmid DNA was obtained using the E.Z.N.A. Plasmid Mini Kit (Omega Bio-tek, Beijing, China). All DNA fragments used for plasmid construction were subjected to agarose gel electrophoresis and then gel-purified using the E.Z.N.A. Gel Extraction Kit (Omega Bio-tek, Beijing, China).
[0095] The enzymes used for PCR amplification, the enzymes required for Gibson assembly, and various restriction endonucleases were all purchased from New England Biolabs (NEB, Beijing, China). Among them, Q5 High-Fidelity DNA Polymerase was used for the amplification of DNA fragments in plasmid construction, and OneTaq 2× Master Mix was used for PCR verification. All experimental operations were carried out strictly in accordance with the product manuals.
[0096] The primers used are listed in Table 1. It includes three expression regulation plasmid systems for realizing the precise positive regulation recombinant plasmid pAND and the negative regulation recombinant plasmid pAND-CRISPRi.
[0097] The specific amplification steps are as follows:
[0098] Using the pBad-sfGFP plasmid as the template and pYY-1F / pYY-1R as the primers to amplify the plasmid vector. Using the pTet-sfGFP plasmid as the template and pTet-1F / pTet-1R as the primers to amplify the pTet promoter. Using the pBad-sfGFP plasmid as the template and araC-1F / araC-1R as the primers to amplify the araC activator protein gene. Using the pBad-sfGFP plasmid as the template and pBad-1F / tetO-pBad-1R as the primers to amplify the pBad promoter. Using the pBad-sfGFP plasmid as the template and sfGFP-1F / sfGFP-1R as the primers to amplify the sfGFP gene. The above DNA fragments were assembled to obtain the positive regulation recombinant plasmid pAND.
[0099] Using the pBad-sfGFP plasmid as a template, the plasmid vector was amplified with pYY-1F / pYY-1R as primers. Using the pTet-sfGFP plasmid as a template, the pTet promoter was amplified with pTet-1F / pTet-1R as primers. Using the pBad-sfGFP plasmid as a template, the araC activator protein gene was amplified with araC-1F / araC-1R as primers. Using the pBad-sfGFP plasmid as a template, the pBad promoter was amplified with pBad-1F / tetO-pBad-1R as primers. Using the pBad-CRISPRi plasmid as a template, the dCas12a gene was amplified with dCas12a-2F / dCas12a-2R as primers. Using the pLac-mCherry plasmid as a template, the constitutive pLac promoter was amplified with pLac-2F / pLac-2R as primers. Using the pBad-CRISPRi plasmid as a template, the DNA fragment of crRNA was amplified with crRNA-2F / crRNA-2R as primers. The above DNA fragments were assembled to obtain the negative regulation recombinant plasmid pAND-CRISPRi.
[0100] IV. Preparation of electrocompetent Escherichia coli
[0101] 1. From the LB liquid medium of E. coli shaken overnight at 200 rpm, 1 mL of the bacterial solution was aspirated and the cells were collected by centrifugation at 12,000 rpm for 2 min.
[0102] 2. The supernatant was discarded, and the cells were suspended in ice-cold 300 mM sucrose. The cells were gently pipetted to suspend them, and after thoroughly suspending and dispersing the precipitated cells, the cells were collected by centrifugation.
[0103] 3. Repeat step 2 once.
[0104] 4. Centrifuge, discard the supernatant, resuspend the cells in 100 μL of 300 mM sucrose, and freeze at -80 °C for later use.
[0105] V. DNA Ligation
[0106] The plasmid was constructed mainly by Gibson ligation. The specific steps are as follows:
[0107] 1. Prepare 6 mL of 5×ISO buffer. The formula is as follows: 3 mL of 1 M Tris-HCl (pH 7.5); 150 μL of 2 M MgCl2; 240 μL of 100 mM dNTP mixture (25 mM each of dGTP, dCTP, dATP, dTTP); 300 μL of 1 M DTT; 1.5 g of PEG-8000; 300 μL of 100 mM NAD; ddH2O was added to make up to 6 mL; after mixing, it was aliquoted, 160 μL per tube, and stored at -20 °C for later use.
[0108] 2. Prepare 600 μL of Gibson ligase mixture with the following components: 160 μL of 5× ISO buffer; 0.32 μL of 10 U / μL T5 exonuclease; 10 μL of 2 U / μL Q5 DNA polymerase; 80 μL of 40 U / μL Taq DNA ligase; make up to 1.2 mL with ddH₂O; mix well and dispense into aliquots of 15 μL each in PCR tubes, and store at -20 °C for later use.
[0109] 3. Before use, take out one tube of 15 μL of Gibson ligation mixture and thaw it on ice for later use.
[0110] 4. Prepare DNA fragments for plasmid construction and measure their DNA concentration (ng / μL) using NanoDrop (Thermo).
[0111] 5. Perform Gibson ligation reaction: Take 100 ng of plasmid backbone DNA, mix it with an equimolar amount of other DNA fragments, mix well by pipetting, then add the Gibson ligation mixture to make the final volume 20 μL, and make up the insufficient volume with double-distilled water (ddH₂O).
[0112] 6. Incubate the reaction system at 50 °C for at least 60 minutes.
[0113] 7. After the reaction is completed, take 1 - 5 μL of the ligation product and transform it into Escherichia coli competent cells for electroporation.
[0114] VI. Electroporation Procedure
[0115] 1. Mix the constructed plasmid or Gibson reaction system well with the competent cells, transfer it to a 2 mm electroporation cuvette, and let it stand on ice for 5 minutes.
[0116] 2. Set the electroporation conditions to 2.5 kV using an electroporator (Bio-Rad) for electroporation; after electroporation is completed, immediately add 1 mL of LB medium and gently invert the tube to mix well.
[0117] 3. Transfer the mixed cell suspension to a 1.5 mL centrifuge tube, incubate it at 37 °C for 1 hour, then spread it on an LB solid plate containing the corresponding antibiotic and incubate it upside down in a constant temperature incubator.
[0118] VII. DNA Sequencing
[0119] Both the constructed plasmid and the PCR products used for verification are confirmed for the correct sequence by sequencing. The sequencing service is completed by Sangon Biotech (Shanghai) Co., Ltd.
[0120] VIII. Construction of Engineered Strains
[0121] The positive regulatory recombinant plasmid pAND and the negative regulatory recombinant plasmid pAND-CRISPRi were respectively electrotransformed into the E. coli WM3064 strain, and then transferred into the target host by conjugation. The target host for the positive regulatory recombinant plasmid was selected as S. oneidensis MR-1, and the target host for the negative regulatory recombinant plasmid was selected as S. oneidensis GZ.
[0122] The specific experimental steps are as follows:
[0123] First, the plasmid was electrotransformed into E. coli WM3064 to serve as the donor strain. For this purpose, electrocompetent cells of E. coli WM3064 were prepared.
[0124] 200 ng of the plasmid was added to the electrocompetent cells, and electrotransformation was performed at 2.5 kV in a pre-chilled 2 mm electroporation cuvette (Bio-Rad Co., USA) using a MicroPulser (Bio-Rad Co., USA). Subsequently, the cells were resuspended in 1 mL of LB medium supplemented with DAP. This suspension was incubated at 37 °C for 1 hour for recovery, and then spread on plates containing DAP and the required antibiotics.
[0125] The E. coli WM3064 (donor cells) containing the recombinant plasmid and the target strain (recipient cells) were mixed at a ratio of 1:1, washed and resuspended with fresh medium, and then spread on a plate containing DAP for static culture. After 24 - 48 hours, the formed biofilm was gently scraped off, resuspended, and spread on a plate containing antibiotics but without DAP to obtain monoclonal colonies. The target engineered bacteria containing the recombinant plasmid were verified by plasmid characterization PCR using appropriate primers. They were inoculated into 5 mL of LB liquid medium containing the corresponding antibiotics, cultured overnight with shaking, and then mixed with an equal volume of sterilized 30% glycerol in a cryotube and stored at -80 °C.
[0126] IX. Induction of the Expression Regulation System
[0127] The engineered bacteria containing the recombinant plasmid were inoculated from the -80 °C cryotube into 5 mL of LB liquid medium at a ratio of 1% (v / v), cultured overnight with shaking, and used as the seed solution. Then, the seed solution was inoculated into 100 mL of LB liquid medium for scale-up culture at a ratio of 1%. When the OD 600 was approximately 0.2, different concentrations of inducers (including 0 - 100 μg / L aTc, 0 - 50 mM L-Ara) were added, and the culture was carried out at 30 °C.
[0128] X. Fluorescent Expression Assay of the Expression Regulation System
[0129] Take 200 μL of the induced bacterial solution and inoculate it into a Falcon 96-well polystyrene microplate (Corning, USA), and then place it on a microplate reader (Synergy H1, BioTek, USA) for continuous detection. Measure the fluorescence intensity of sfGFP or GFPmut3b at an excitation / emission wavelength of 485 / 525 nm.
[0130] XI. Experimental Results
[0131] For the positive regulation recombinant system, as Figure 8 shown, compared with the linear one-dimensional regulation presented by the ordinary induction system (pBad-sfGFP), the positive regulation recombinant plasmid pAND constructed by us can achieve two-dimensional planar expression regulation, showing higher resolution and a wider regulation range at the output level. Among them, the pAND system exhibits lower background leakage expression and higher maximum expression intensity, and its dynamic range reaches 389 times respectively, while the dynamic range of the traditional induction system is only about 100 times.
[0132] Compared with the single pTet in the comparative document and the prior art pBad expression system, the novel expression regulation system pAND of the present invention has lower background leakage, faster response rate, larger expression range and stronger expression intensity, and the expression is more homogeneous. As Figure 9 and Figure 10 shown, compared with the background leakage expression shown by the induction system pBad when not induced, no obvious background expression was observed in pAND, indicating that it has an extremely low background leakage level. Under activation at different time points, pAND generally shows a faster and stronger response ability. And the earlier the activation, the higher the intensity and the faster the response. At the activation time points of 3 - 9 hours, pAND shows a sharper response curve and higher maximum output; after 12 hours, the output of the control system has decreased significantly, but pAND still maintains a significant output level. In addition, the maximum output intensity of pAND is increased to 1.56 - 7.73 times that of the control system. In addition, the slope of the response curve was calculated to quantify the response speed, and the results show that at all time points, the pAND system shows a faster response, increased to 1.41 - 5.95 times that of the pBad control. As Figure 11 shown, analyze the single-cell homogeneity of the population expression of microorganisms during the response process. Due to the slower response time of the traditional induction pBad system, it shows longer intercellular heterogeneity during the induction process. While the pAND system can make the population reach a homogeneous expression state in a shorter time, significantly improving the homogeneity of the cell population.
[0133] For the negative regulation recombination system, such as Figure 12 As shown, compared with the 64% inhibition efficiency achieved by assembling CRISPRi (pBad-CRISPRi) under the ordinary induction system, the negative regulation recombinant plasmid pAND-CRISPRi of the present invention can achieve an inhibition efficiency of 90%.
[0134] XII. Summary of the overall concept of the present invention:
[0135] In the present invention, two additional operators (tetO) are added downstream of the traditional activation induction system (taking pBad as an example) and in front of the activation protein gene (araC), and the activation protein gene (araC) is expressed by using the traditional induction system (taking pTet as an example). Through the double-operator repression and the cascade amplification effect of activation protein accumulation, lower background leakage, faster response rate, larger expression range, stronger expression intensity of the target gene are achieved, and the expression is more homogeneous.
[0136] The expression regulation recombinant plasmid constructed in the present invention can achieve a rapid response of the target gene expression through the concentration ratio of two different inducers (aTc, L-Ara). With the help of the positive and negative expression regulation systems, the positive expression and targeted inhibition of the target gene after signal amplification and rapid response can be achieved respectively.
[0137] The above are only the preferred embodiments of the present invention. It should be noted that for those of ordinary skill in the art, without departing from the principle of the present invention, several improvements and modifications can be made, and these improvements and modifications should also be regarded as the protection scope of the present invention.
Claims
1. A molecular switch, characterized in that, It includes the activator protein araC gene, pTet promoter, repressor protein tetR gene, pBad promoter and tetO operator connected from upstream to downstream.
2. Positive regulation system, characterized in that, It includes the molecular switch described in claim 1 and the target gene.
3. Reverse regulation system, characterized in that, It includes the molecular switch described in claim 1, dCas12a gene, constitutive promoter and crRNA targeting the target gene.
4. The reverse regulation system according to claim 3, characterized in that The coding product of the dCas12a gene is derived from Francisella novicida U112 and has an E1006A mutation; The constitutive promoter includes the pLac promoter.
5. Recombinant vector, characterized in that, It includes a vector backbone and at least one of the following I) - III): I) The molecular switch described in claim 1; II) The forward regulation system described in claim 2; III) The reverse regulation system described in claim 3 or 4.
6. A host cell, characterized in that, Transfect or transform the recombinant vector as described in claim 5.
7. The method for constructing the recombinant vector according to claim 5, characterized in that, It includes culturing the host cell as described in claim 6 to obtain the recombinant vector as described in claim 5.
8. A product for gene expression or regulation, characterized in that, It includes reagents for gene expression or regulation and at least one of the following i) - iii): i) The recombinant vector as described in claim 5; ii) The host cell as described in claim 6; iii) The recombinant vector obtained by the construction method described in claim 7.
9. The product according to claim 8, characterized in that, The reagents for gene expression or regulation include induction reagents, buffers, antibiotics, culture media and / or conjugative transfer ligand bacteria.
10. Use of any one of the following A) - G) in gene expression and / or regulation: A) The molecular switch described in claim 1; B) The forward regulation system described in claim 2; C) The reverse regulation system described in claim 3 or 4; D) The recombinant vector as described in claim 5; E) The host cell as described in claim 6; F) The recombinant vector obtained by the construction method described in claim 7; G) The product described in claim 8 or 9.
Citation Information
Cited By
Product, system and method of cell cultivation
US12668774B2
Culture media based on protein hydrolysate and a process for preparing thereof
US12686847B2
